Karger Kompass Dermatol DOI: 10.1159/000453571
Übersetzung aus Curr Probl Dermatol. Basel, Karger, 2016, vol 49, pp 90–102 (DOI: 10.1159/000441548)

Literatur

1. Proksch E, Brandner JM, Jensen JM: The skin: an indispensable barrier. Exp Dermatol 2008;17:1063-1072.
2. Candi E, Schmidt R, Melino G: The cornified envelope: a model of cell death in the skin. Nat Rev Mol Cell Biol 2005;6:328-340.
3. Thyssen JP, Kezic S: Causes of epidermal filaggrin reduction and their role in the pathogenesis of atopic dermatitis. J Allergy Clin Immunol 2014;134:792-799.
4. Thyssen JP, Godoy-Gijon E, Elias PM: Ichthyosis vulgaris: the filaggrin mutation disease. Br J Dermatol 2013;168:1155-1166.
5. Smith FJ, Irvine AD, Terron-Kwiatkowski A, et al: Loss-of-function mutations in the gene encoding filaggrin cause ichthyosis vulgaris. Nat Genet 2006;38:337-342.
6. Katagiri C, Sato J, Nomura J, Denda M: Changes in environmental humidity affect the water-holding property of the stratum corneum and its free amino acid content, and the expression of filaggrin in the epidermis of hairless mice. J Dermatol Sci 2003;31:29-35.
7. Pellerin L, Henry J, Hsu CY, et al: Defects of filaggrin-like proteins in both lesional and nonlesional atopic skin. J Allergy Clin Immunol 2013;131: 1094-1102.
8. Howell MD, Kim BE, Gao P, et al: Modulation of filaggrin by Th2 cytokines in the skin of atopic dermatitis (AD). J Allergy Clin Immunol 2007;119:S283.
9. Howell MD, Kim BE, Gao P, et al: Cytokine modulation of atopic dermatitis filaggrin skin expression. J Allergy Clin Immunol 2009;124(3 suppl 2):R7-R12.
10. Thyssen JP, Linneberg A, Menné T, Johansen JD: The epidemiology of contact allergy in the general population - prevalence and main findings. Contact Dermatitis 2007;57:287-299.
11. Martin SF: Contact dermatitis: from pathomechanisms to immunotoxicology. Exp Dermatol 2012;21:382-389.
12. Berard F, Marty JP, Nicolas JF: Allergen penetration through the skin. Eur J Dermatol 2003;13:324-330.
13. Kimber I, Basketter DA, Gerberick GF, Dearman RJ: Allergic contact dermatitis. Int Immunopharmacol 2002;2:201-211.
14. Thyssen JP, McFadden JP, Kimber I: The multiple factors affecting the association between atopic dermatitis and contact sensitization. Allergy 2014;69:28-36.
15. Lebwohl M: Psoriasis. Lancet 2003;361:1197-1204.
16. Smith CH, Barker JN: Psoriasis and its management. BMJ 2006;333:380-384.
17. Steinman L: A brief history of T(H)17, the first major revision in the T(H)1/T(H)2 hypothesis of T cell-mediated tissue damage. Nat Med 2007;13:139-145.
18. Pene J, Chevalier S, Preisser L, et al: Chronically inflamed human tissues are infiltrated by highly differentiated Th17 lymphocytes. J Immunol 2008;180:7423-7430.
19. Kagami S, Rizzo HL, Lee JJ, et al: Circulating Th17, Th22, and Th1 cells are increased in psoriasis. J Invest Dermatol 2010;130:1373-1383.
20. Lowes MA, Kikuchi T, Fuentes-Duculan J, et al: Psoriasis vulgaris lesions contain discrete populations of Th1 and Th17 T cells. J Invest Dermatol 2008;128:1207-1211.
21. Wilson NJ, Boniface K, Chan JR, et al: Development, cytokine profile and function of human interleukin 17-producing helper T cells. Nat Immunol 2007;8:950-957.
22. McGeachy MJ, Chen Y, Tato CM, et al: The interleukin 23 receptor is essential for the terminal differentiation of interleukin 17-producing effector T helper cells in vivo. Nat Immunol 2009;10:314-324.
23. Papp KA, Langley RG, Lebwohl M, et al: Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet 2008;371:1675-1684.
24. Takahashi H, Tsuji H, Minami-Hori M, et al: Defective barrier function accompanied by structural changes of psoriatic stratum corneum. J Dermatol 2014;41:144-148.
25. Motta S, Monti M, Sesana S, et al: Abnormality of water barrier function in psoriasis. Role of ceramide fractions. Arch Dermatol 1994;130:452-456.

26. Tagami H, Yoshikuni K: Interrelationship between water-barrier and reservoir functions of pathologic stratum-corneum. Arch Dermatol 1985;121:642-645.
27. Grice K, Sattar H, Baker H: The cutaneous barrier to salts and water in psoriasis and in normal skin. Br J Dermatol 1973;88:459-463.
28. Fartasch M: Epidermal barrier in disorders of the skin. Microsc Res Tech 1997;38:361-372.
29. Huffmeier U, Traupe H, Oji V, et al: Loss-of-function variants of the filaggrin gene are not major susceptibility factors for psoriasis vulgaris or psoriatic arthritis in German patients. J Invest Dermatol 2007;127:1367-1370.
30. Weichenthal M, Ruether A, Schreiber S, et al: Filaggrin R501X and 2282del4 mutations are not associated with chronic plaque-type psoriasis in a German cohort. J Invest Dermatol 2007;127:1535-1537.
31. Giardina E, Paolillo N, Sinibaldi C, Novelli G: R501X and 2282del4 filaggrin mutations do not confer susceptibility to psoriasis and atopic dermatitis in Italian patients. Dermatology 2008;216:83-84.
32. Thyssen JP, Johansen JD, Carlsen BC, et al: The filaggrin null genotypes R501X and 2282del4 seem not to be associated with psoriasis: results from general population study and meta-analysis. J Eur Acad Dermatol Venereol 2012;26:782-784.
33. Winge MC, Suneson J, Lysell J, et al: Lack of association between filaggrin gene mutations and onset of psoriasis in childhood. J Eur Acad Dermatol Venereol 2013;27:e124-e127.
34. Zhao Y, Terron-Kwiatkowski A, Liao H, et al: Filaggrin null alleles are not associated with psoriasis. J Invest Dermatol 2007;127:1878-1882.
35. Bernard BA, Asselineau D, Schaffar- Deshayes L, Darmon MY: Abnormal sequence of expression of differentiation markers in psoriatic epidermis: inversion of two steps in the differentiation program? J Invest Dermatol 1988;90:801-805.
36. Watanabe S, Wagatsuma K, Ichikawa E, Takahashi H: Abnormal distribution of epidermal protein antigens in psoriatic epidermis. J Dermatol 1991;18:143-151.
37. Gerritsen MJ, Elbers ME, de Jong EM, van de Kerkhof PC: Recruitment of cycling epidermal cells and expression of filaggrin, involucrin and tenascin in the margin of the active psoriatic plaque, in the uninvolved skin of psoriatic patients and in the normal healthy skin. J Dermatol Sci 1997;14:179-188.
38. Elias PM, Ahn SK, Denda M, et al: Modulations in epidermal calcium regulate the expression of differentiation-specific markers. J Invest Dermatol 2002;119:1128-1136.
39. Fischer M, William T, Helmbold P, et al: Expression of epidermal N-methyl-D-aspartate receptors (NMDAR1) depends on formation of the granular layer - analysis in diseases with parakeratotic cornification. Arch Dermatol Res 2004;296:157-162.
40. Kristensen M, Chu CQ, Eedy DJ, et al: Localization of tumour necrosis factor-alpha (TNF-alpha) and its receptors in normal and psoriatic skin: epidermal cells express the 55-kD but not the 75-kD TNF receptor. Clin Exp Immunol 1993;94:354-362.
41. Ettehadi P, Greaves MW, Wallach D, et al: Elevated tumour necrosis factor- alpha (TNF-alpha) biological activity in psoriatic skin lesions. Clin Exp Immunol 1994;96:146-151.
42. Hvid M, Johansen C, Deleuran B, et al: Regulation of caspase 14 expression in keratinocytes by inflammatory cytokines - a possible link between reduced skin barrier function and inflammation? Exp Dermatol 2011;20:633-636.
43. Gutowska-Owsiak D, Schaupp AL, Salimi M, et al: IL-17 downregulates filaggrin and affects keratinocyte expression of genes associated with cellular adhesion. Exp Dermatol 2012;21:104-110.
44. de Cid R, Riveira-Munoz E, Zeeuwen PL, et al: Deletion of the late cornified envelope LCE3B and LCE3C genes as a susceptibility factor for psoriasis. Nat Genet 2009;41:211-215.
45. Eyre RW, Krueger GG: Response to injury of skin involved and uninvolved with psoriasis, and its relation to disease activity: Koebner and 'reverse' Koebner reactions. Br J Dermatol 1982;106:153-159.
46. Friedman SJ: Management of psoriasis vulgaris with a hydrocolloid occlusive dressing. Arch Dermatol 1987;123:1046-1052.
47. Nickoloff BJ, Naidu Y: Perturbation of epidermal barrier function correlates with initiation of cytokine cascade in human skin. J Am Acad Dermatol 1994;30:535-546.
48. Engkilde K, Menne T, Johansen JD: Inverse relationship between allergic contact dermatitis and type 1 diabetes mellitus: a retrospective clinic-based study. Diabetologia 2006;49:644-647.
49. Engkilde K, Thyssen JP, Bangsgaard N, et al: Inverse association between rheumatoid arthritis and contact allergy. Acta Derm Venereol 2012;92:175-176.
50. Engkilde K, Menne T, Johansen JD: Inflammatory bowel disease in relation to contact allergy: a patient-based study. Scand J Gastroenterol 2007;42:572-576.
51. Fedler R, Stromer K: Nickel sensitivity in atopics, psoriatics and healthy subjects. Contact Dermatitis 1993;29:65-69.
52. Barile M, Cozzani E, Anonide A, et al: Is contact allergy rare in psoriatics? Contact Dermatitis 1996;35:113-114.
53. Jovanović M, Boza P, Karadaglić D, et al: Contact sensitivity in patients with psoriasis in Vojvodina. Int Arch Allergy Immunol 2009;148:311-320.

54. Heule F, Tahapary GJ, Bello CR, van Joost T: Delayed-type hypersensitivity to contact allergens in psoriasis. A clinical evaluation. Contact Dermatitis 1998;38:78-82.
55. Henseler T, Christophers E: Disease concomitance in psoriasis. J Am Acad Dermatol 1995;32:982-986.
56. Bangsgaard N, Engkilde K, Thyssen JP, et al: Inverse relationship between contact allergy and psoriasis: results from a patient- and a population-based study. Br J Dermatol 2009;161:1119-1123.
57. Moss C, Friedmann PS, Shuster S: Impaired contact hypersensitivity in untreated psoriasis and the effects of photochemotherapy and dithranol/UV-B. Br J Dermatol 1981;105:503-508.
58. Obalek S, Haftek M, Slinski W: Immunological studies in psoriasis. The quantitative evaluation of cell-mediated immunity in patients with psoriasis by experimental sensitization to 2,4-dinitrochlorobenzene. Dermatologica 1977;155:13-25.
59. Bangsgaard N, Engkilde K, Menné T, et al: Impaired hapten sensitization in patients with autoimmune disease. Clin Exp Immunol 2011;165:310-317.
60. Epstein WL, Jessar RA: Contact-type delayed hypersensitivity in patients with rheumatoid arthritis. Arthritis Rheum 1959;2:178-181.
61. Malhotra V, Kaur I, Saraswat A, Kumar B: Frequency of patch-test positivity in patients with psoriasis: a prospective controlled study. Acta Derm Venereol 2002;82:432-435.
62. Cumberbatch M, Singh M, Dearman RJ, et al: Impaired Langerhans cell migration in psoriasis. J Exp Med 2006;203:953-960.
63. Quaranta M, Eyerich S, Knapp B, et al: Allergic contact dermatitis in psoriasis patients: typical, delayed, and non-interacting. PLoS One 2014;9:e101814.
64. Bieber T: Atopic dermatitis. N Engl J Med 2008;358:1483-1494.
65. Ober C, Yao TC: The genetics of asthma and allergic disease: a 21st century perspective. Immunol Rev 2011;242:10-30.
66. Eyerich K, Novak N: Immunology of atopic eczema: overcoming the Th1/Th2 paradigm. Allergy 2013;68:974-982.
67. Dharmage SC, Lowe AJ, Matheson MC, et al: Atopic dermatitis and the atopic march revisited. Allergy 2014;69:17-27.
68. Jensen JM, Fölster-Holst R, Baranowsky A, et al: Impaired sphingomyelinase activity and epidermal differentiation in atopic dermatitis. J Invest Dermatol 2004;122:1423-1431.
69. Polańska A, Dańczak-Pazdrowska A, Silny W, et al: Nonlesional skin in atopic dermatitis is seemingly healthy skin - observations using noninvasive methods. Wideochir Inne Tech Maloinwazyjne 2013;8:192-199.
70. Holm EA, Wulf HC, Thomassen L, Jemec GB: Instrumental assessment of atopic eczema: validation of transepidermal water loss, stratum corneum hydration, erythema, scaling, and edema. J Am Acad Dermatol 2006;55:772-780.
71. Gupta J, Grube E, Ericksen MB, et al: Intrinsically defective skin barrier function in children with atopic dermatitis correlates with disease severity. J Allergy Clin Immunol 2008;121:725.e2-730.e2.
72. Cookson W: The immunogenetics of asthma and eczema: a new focus on the epithelium. Nat Rev Immunol 2004;4:978-988.
73. Jakobza D, Reichmann G, Langnick W, et al: Surface skin lipids in atopic dermatitis (in German). Dermatol Monatsschr 1981;167:26-29.
74. Di Nardo A, Wertz P, Giannetti A, Seidenari S: Ceramide and cholesterol composition of the skin of patients with atopic dermatitis. Acta Derm Venereol 1998;78:27-30.
75. van Smeden J, Janssens M, Kaye EC, et al: The importance of free fatty acid chain length for the skin barrier function in atopic eczema patients. Exp Dermatol 2014;23:45-52.
76. Palmer CN, Irvine AD, Terron-Kwiatkowski A, et al: Common loss-of-function variants of the epidermal barrier protein filaggrin are a major predisposing factor for atopic dermatitis. Nat Genet 2006;38:441-446.
77. Ross-Hansen K, Østergaard O, Tanassi JT, et al: Filaggrin is a predominant member of the denaturation-resistant nickel-binding proteome of human epidermis. J Invest Dermatol 2014;134:1164-1166.
78. Wezynfeld NE, Goch W, Bal W, Frączyk T: cis-Urocanic acid as a potential nickel(II) binding molecule in the human skin. Dalton Trans 2014;43:3196-3201.
79. Novak N, Baurecht H, Schäfer T, et al: Loss-of-function mutations in the filaggrin gene and allergic contact sensitization to nickel. J Invest Dermatol 2008;128:1430-1435.
80. Thyssen JP, Johansen JD, Linneberg A, et al: The association between null mutations in the filaggrin gene and contact sensitization to nickel and other chemicals in the general population. Br J Dermatol 2010;162:1278-1285.
81. Ross-Hansen K, Menné T, Johansen JD, et al: Nickel reactivity and filaggrin null mutations - evaluation of the filaggrin bypass theory in a general population. Contact Dermatitis 2011;64:24-31.
82. Hegewald J, Uter W, Pfahlberg A, et al: A multifactorial analysis of concurrent patch-test reactions to nickel, cobalt, and chromate. Allergy 2005;60:372-378.
83. Dotterud LK, Falk ES: Metal allergy in north Norwegian schoolchildren and its relationship with ear piercing and atopy. Contact Dermatitis 1994;31:308-313.

84. Malajian D, Belsito DV: Cutaneous delayed-type hypersensitivity in patients with atopic dermatitis. J Am Acad Dermatol 2013;69:232-237.
85. Mortz CG, Bindslev-Jensen C, Andersen KE: Nickel allergy from adolescence to adulthood in the TOACS cohort. Contact Dermatitis 2013;68:348-356.
86. Thyssen JP, Linneberg A, Ross-Hansen K, et al: Filaggrin mutations are strongly associated with contact sensitization in individuals with dermatitis. Contact Dermatitis 2013;68:273-276.
87. Hata M, Tokura Y, Takigawa M, et al: Assessment of epidermal barrier function by photoacoustic spectrometry in relation to its importance in the pathogenesis of atopic dermatitis. Lab Invest 2002;82:1451-1461.
88. Jakasa I, Verberk MM, Esposito M, et al: Altered penetration of polyethylene glycols into uninvolved skin of atopic dermatitis patients. J Invest Dermatol 2007;127:129-134.
89. Jakasa I, de Jongh CM, Verberk MM, et al: Percutaneous penetration of sodium lauryl sulphate is increased in uninvolved skin of patients with atopic dermatitis compared with control subjects. Br J Dermatol 2006;155:104-109.
90. Ballardini N, Kull I, Söderhäll C, et al: Eczema severity in preadolescent children and its relation to sex, filaggrin mutations, asthma, rhinitis, aggravating factors and topical treatment: a report from the BAMSE birth cohort. Br J Dermatol 2013;168:588-594.
91. Hamann CR, Bernard S, Hamann D, et al: Is there a risk using hypoallergenic cosmetic pediatric products in the United States? J Allergy Clin Immunol 2015;135:1070-1071.
92. Shaughnessy CN, Malajian D, Belsito DV: Cutaneous delayed-type hypersensitivity in patients with atopic dermatitis: reactivity to topical preservatives. J Am Acad Dermatol 2014;70:102-107.
93. Vind-Kezunovic D, Johansen JD, Carlsen BC: Prevalence of and factors influencing sensitization to corticosteroids in a Danish patch test population. Contact Dermatitis 2011;64:325-329.
94. Thyssen JP, Linneberg A, Engkilde K, et al: Contact sensitization to common haptens is associated with atopic dermatitis: new insight. Br J Dermatol 2012;166:1255-1261.
95. Rystedt I: Contact sensitivity in adults with atopic dermatitis in childhood. Contact Dermatitis 1985;13:1-8.
96. Heine G, Schnuch A, Uter W, et al: Type-IV sensitization profile of individuals with atopic eczema: results from the Information Network of Departments of Dermatology (IVDK) and the German Contact Dermatitis Research Group (DKG). Allergy 2006;61:611-616.
97. Herro EM, Matiz C, Sullivan K, et al: Frequency of contact allergens in pediatric patients with atopic dermatitis. J Clin Aesthet Dermatol 2011;4:39-41.
98. Warshaw EM, Nelsen DD, Maibach HI, et al: Positive patch test reactions to lanolin: cross-sectional data from the North American Contact Dermatitis Group, 1994 to 2006. Dermatitis 2009;20:79-88.
99. Carlsen BC, Andersen KE, Menné T, Johansen JD: Characterization of the polysensitized patient: a matched case-control study. Contact Dermatitis 2009;61:22-30.
100. Schwitulla J, Gefeller O, Schnuch A, Uter W: Risk factors of polysensitization to contact allergens. Br J Dermatol 2013;169:611-617.
101. Clemmensen KK, Thomsen SF, Jemec GB, Agner T: Pattern of contact sensitization in patients with and without atopic dermatitis in a hospital-based clinical database. Contact Dermatitis 2014;71:75-81.
102. Dhingra N, Shemer A, Correa da Rosa J, et al: Molecular profiling of contact dermatitis skin identifies allergen- dependent differences in immune response. J Allergy Clin Immunol 2014;134:362-372.
103. Buckley DA, Basketter DA, Kan-King-Yu D, et al: Atopy and contact allergy to fragrance: allergic reactions to the fragrance mix I (the Larsen mix). Contact Dermatitis 2008;59:220-225.
104. Cronin E, Mcfadden JP: Patients with atopic eczema do become sensitized to contact allergens. Contact Dermatitis 1993;28:225-228.
105. Storrs FJ, White CR Jr: False-positive 'poral' cobalt patch test reactions reside in the eccrine acrosyringium. Cutis 2000;65:49-53.
106. Uehara M, Takahashi C, Ofuji S: Pustular patch test reactions in atopic dermatitis. Arch Dermatol 1975;111:1154-1157.
107. Brasch J, Schnuch A, Uter W: Patch-test reaction patterns in patients with a predisposition to atopic dermatitis. Contact Dermatitis 2003;49:197-201.
108. Uehara M, Sawai T: A longitudinal study of contact sensitivity in patients with atopic dermatitis. Arch Dermatol 1989;125:366-368.
109. Rees J, Friedmann PS, Matthews JN: Contact sensitivity to dinitrochlorobenzene is impaired in atopic subjects. Controversy revisited. Arch Dermatol 1990;126:1173-1175.
110. Jones HE, Lewis CW, McMarlin SL: Allergic contact sensitivity in atopic dermatitis. Arch Dermatol 1973;107:217-222.
111. Thyssen JP, Johansen JD, Linneberg A, et al: The association between contact sensitization and atopic disease by linkage of a clinical database and a nationwide patient registry. Allergy 2012;67:1157-1164.
112. Martin SF, Esser PR, Weber FC, et al: Mechanisms of chemical-induced innate immunity in allergic contact dermatitis. Allergy 2011;66:1152-1163.

113. Newell L, Polak ME, Perera J, et al: Sensitization via healthy skin programs Th2 responses in individuals with atopic dermatitis. J Invest Dermatol 2013;133:2372-2380.
114. Cavani A, Pennino D, Eyerich K: Th17 and Th22 in skin allergy. Chem Immunol Allergy 2012;96:39-44.
115. Agrawal R, Wisniewski JA, Woodfolk JA: The role of regulatory T cells in atopic dermatitis. Curr Probl Dermatol 2011;41:112-124.
116. Kezic S: Genetic susceptibility to occupational contact dermatitis. Int J Immunopathol Pharmacol 2011; 24(1 suppl):73S-78S.
117. Ale IS, Maibach HI: Irritant contact dermatitis. Rev Environ Health 2014;29:195-206.
118. Diepgen TL: Occupational skin-disease data in Europe. Int Arch Occup Environ Health 2003;76:331-338.
119. Smith HR, Basketter DA, McFadden JP: Irritant dermatitis, irritancy and its role in allergic contact dermatitis. Clin Exp Dermatol 2002;27:138-146.
120. Coenraads PJ, Diepgen TL: Risk for hand eczema in employees with past or present atopic dermatitis. Int Arch Occup Environ Health 1998;71:7-13.
121. Dickel H, Bruckner TM, Schmidt A, Diepgen TL: Impact of atopic skin diathesis on occupational skin disease incidence in a working population. J Invest Dermatol 2003;121:37-40.
122. de Jongh CM, Khrenova L, Verberk MM, et al: Loss-of-function polymorphisms in the filaggrin gene are associated with an increased susceptibility to chronic irritant contact dermatitis: a case-control study. Br J Dermatol 2008;159:621-627.
123. Visser MJ, Landeck L, Campbell LE, et al: Impact of atopic dermatitis and loss-of-function mutations in the filaggrin gene on the development of occupational irritant contact dermatitis. Br J Dermatol 2013;168:326-332.
124. Lee JY, Effendy I, Maibach HI: Acute irritant contact dermatitis: recovery time in man. Contact Dermatitis 1997;36:285-290.
125. Fartasch M, Schnetz E, Diepgen TL: Characterization of detergent-induced barrier alterations - effect of barrier cream on irritation. J Investig Dermatol Symp Proc 1998;3:121-127.
126. Wood LC, Jackson SM, Elias PM, et al: Cutaneous barrier perturbation stimulates cytokine production in the epidermis of mice. J Clin Invest 1992;90:482-487.
127. Nilzen A, Wikstrom K: The influence of lauryl sulphate on the sensitization of guineapigs to chrome and nickle. Acta Derm Venereol 1955;35:292-299.
128. Magnusson B, Kligman AM: Allergic Contact Dermatitis in the Guinea Pig. Springfield, Thomas, 1970.
129. Basketter DA: Guinea pig predictive test for contact hypersensitivity; in Dean JH, Luster MI, Munson AE, Kimber I (eds): Immunotoxicology and Immunopharmacology. London, Raven, 1994, pp 693-702.
130. McLelland J, Shuster S, Matthews JN: 'Irritants' increase the response to an allergen in allergic contact dermatitis. Arch Dermatol 1991;127:1016-1019.
131. Allenby CF, Basketter DA: Minimum eliciting patch test concentrations of cobalt. Contact Dermatitis 1989;20:185-190.
132. Allenby CF, Basketter DA: An arm immersion model of compromised skin (II). Influence on minimal eliciting patch test concentrations of nickel. Contact Dermatitis 1993;28:129-133.
133. Agner T, Johansen JD, Overgaard L, et al: Combined effects of irritants and allergens. Synergistic effects of nickel and sodium lauryl sulfate in nickel-sensitized individuals. Contact Dermatitis 2002;47:21-26.
134. Barker JN, Mitra RS, Griffiths CE, et al: Keratinocytes as initiators of inflammation. Lancet 1991;337:211-214.
135. Cumberbatch M, Dearman RJ, Griffiths CE, Kimber I: Langerhans cell migration. Clin Exp Dermatol 2000;25:413-418.
136. Schwarzenberger K, Udey MC: Contact allergens and epidermal proinflammatory cytokines modulate Langerhans cell E-cadherin expression in situ. J Invest Dermatol 1996;106:553-558.
137. Kobayashi Y: Langerhans' cells produce type IV collagenase (MMP-9) following epicutaneous stimulation with haptens. Immunology 1997;90:496-501.
138. Cumberbatch M, Kimber I: Tumour necrosis factor-alpha is required for accumulation of dendritic cells in draining lymph nodes and for optimal contact sensitization. Immunology 1995;84:31-35.